TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms
暂无分享,去创建一个
Anna L. Brown | H. Scott | A. Tefferi | Sharad Kumar | Dong Chen | D. Ladon | C. Hahn | M. Shah | C. Kok | A. Al-Kali | N. Gangat | H. Alkhateeb | P. Greipp | D. Singhal | D. Hiwase | R. Chhetri | A. Baranwal | Daniel Thomas | M. Patnaik | Elizabeth Ngoc Hoa Tran | Syed Shah | Carl T. Shultz | Mrinal M. Patnaik
[1] V. Rotter,et al. Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis , 2023, Nature Communications.
[2] Anna L. Brown,et al. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. , 2022, Blood.
[3] T. Haferlach,et al. Interplay of TP53 Allelic State, Blast Count and Karyotype on Survival of Patients with AML and MDS , 2022, Blood.
[4] J. Lancet,et al. Characterization of TP53-Mutated Myelodysplastic Syndromes and Impact of Allelic Status and Concurrent Cytogenetic Abnormalities on Survival Outcomes , 2022, Blood.
[5] Sharad Kumar,et al. A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure , 2022, Leukemia.
[6] A. Krasnitz,et al. Ordered and deterministic cancer genome evolution after p53 loss , 2022, Nature.
[7] A. Tefferi,et al. Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms , 2022, Blood Cancer Journal.
[8] M. Loh,et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. , 2022, Blood.
[9] Y. Natkunam,et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms , 2022, Leukemia.
[10] A. Wei,et al. Outcomes following venetoclax‐based treatment in therapy‐related myeloid neoplasms , 2022, American journal of hematology.
[11] Andrew T Nguyen,et al. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms , 2022, Blood.
[12] K. Bhalla,et al. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia , 2022, Blood.
[13] M. Jongen‐Lavrencic,et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome , 2022, Blood.
[14] P. D. Dal Cin,et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML , 2022, Blood advances.
[15] Benjamin L. Ebert,et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes , 2019, Nature Medicine.
[16] M. Konopleva,et al. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. , 2020, Blood advances.
[17] K. Pradhan,et al. Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. , 2019, Blood advances.
[18] Anna L. Brown,et al. The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution , 2019, Leukemia.
[19] C. Bloomfield,et al. Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically , 2019, Leukemia.
[20] P. Campbell,et al. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups , 2019, Leukemia.
[21] J. Welch. Patterns of mutations in TP53 mutated AML. , 2018, Best practice & research. Clinical haematology.
[22] M. Konopleva,et al. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms , 2018, Oncotarget.
[23] Megan E. McNerney,et al. Therapy-related myeloid neoplasms: when genetics and environment collide , 2017, Nature Reviews Cancer.
[24] D. Neuberg,et al. Prognostic Mutations in Myelodysplastic Syndrome after Stem‐Cell Transplantation , 2017, The New England journal of medicine.
[25] A. LaCasce,et al. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] W. Hiddemann,et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. , 2016, Blood.
[27] J. Maciejewski,et al. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes , 2016, Leukemia.
[28] J. Maciejewski,et al. High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort , 2016, Leukemia.
[29] S. Nahas,et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes , 2016, Leukemia.
[30] M. Konopleva,et al. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents , 2016, Oncotarget.
[31] B. Ko,et al. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution , 2015, Blood Cancer Journal.
[32] Ken H. Young,et al. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. , 2015, Leukemia research.
[33] Christopher A. Miller,et al. The Role of TP53 Mutations in the Origin and Evolution of Therapy-Related AML , 2014, Nature.
[34] C. Preudhomme,et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. , 2014, Leukemia research.
[35] Benjamin J. Raphael,et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.
[36] A. Stamatoullas,et al. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion , 2012, Genes, chromosomes & cancer.
[37] C. Steidl,et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] S. Fröhling,et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. , 2012, Blood.
[39] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[40] R. Hills,et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.